MedTrace Logo

Study to Evaluate the Efficacy and Safety of PT20 in Subjects With Hyperphosphataemia and Dialysis Dependent Chronic Kidney Disease

NCT02151643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 153

Last updated 2018-01-16

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to see whether PT20 can help people with a high level of phosphate in their blood (called Hyperphosphatemia) that are being treated with dialysis for kidney disease.

Conditions

  • Hyperphosphataemia

Interventions

DRUG

PT20

Modified ferric oxide adipate tablets

DRUG

Placebo

Placebo tablets matched to each PT20 dose arm

Sponsors & Collaborators

  • Clinipace Worldwide

    collaborator INDUSTRY

  • Phosphate Therapeutics

    lead INDUSTRY

Principal Investigators

  • Geoff Block, MD · Denver Nephrologist

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-07
Primary Completion
2015-03-18
Completion
2015-03-18
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02151643 on ClinicalTrials.gov